Infosys Limited today announced the launch of an all-new, personalized medicine solution for the pharmaceutical industry. The solution leverages SAP S/4HANA®, the SAP C/4HANA® suite, the SAP® Analytics Cloud solution, and SCI® platform to derive intelligent insights, enabling pharmaceutical companies to address critical business and regulatory requirements while delivering personalized experiences to patients.
The Infosys personalized medicine solution enables pharma companies to digitally transform their processes and drive stronger business outcomes. The modular solution uses advanced analytics to manage individual patient treatment lifecycle from enrollment and scheduling to post medical treatments and can notably reduce patient treatment lifecycle.
It uses IoT and blockchain to manage critical cold chains and outcome-based invoicing. The solution incorporates seamlessly into an existing business process with minimal disruptions, reducing implementation time, thus enabling quicker product launches for pharma
companies.
Subhro Mallik, SVP & Global Head of Life Sciences, Infosys said, “With rapid growth in digital technologies and advances in biology, the personalized medicine market is projected to grow significantly, and we see a huge opportunity in this space. Digital technologies can help pharma companies accelerate their time to market and provide better patient experiences. Our Personalized Medicine Solution, leveraging SAP S/4HANA, will help ensure that traditional pharma companies are able to digitally transform themselves with minimum disruption.”
Infosys Ltd ended at Rs731.45 down by Rs16.7 or 2.23% from its previous closing of Rs748.15 on the BSE.
